Application Value of Cardiometabolic Index for the Screening of Obstructive Sleep Apnea with or Without Metabolic Syndrome
Donghao Wang,Yating Chen,Yutong Ding,Yongkang Tang,Xiaofen Su,Shiwei Li,Haojie Zhang,Yanyan Zhou,Zhiyang Zhuang,Qiming Gan,Jingcun Wang,Yuting Zhang,Dongxing Zhao,Nuofu Zhang
DOI: https://doi.org/10.2147/nss.s449862
2024-02-19
Nature and Science of Sleep
Abstract:Donghao Wang, 1, &ast Yating Chen, 1, &ast Yutong Ding, 1, &ast Yongkang Tang, 1, &ast Xiaofen Su, 1, &ast Shiwei Li, 1 Haojie Zhang, 1, 2 Yanyan Zhou, 1 Zhiyang Zhuang, 1 Qiming Gan, 1 Jingcun Wang, 1 Yuting Zhang, 1 Dongxing Zhao, 1 Nuofu Zhang 1 1 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Sleep Medicine Center, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510160, People's Republic of China; 2 The Clinical Medicine Department, Henan University, Zhengzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Nuofu Zhang, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Sleep Medicine Center, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510160, People's Republic of China, Tel +86-13600460056, Email Background: Obstructive sleep apnea (OSA) is a common chronic disease with various comorbidities. The cardiometabolic index (CMI) reflects visceral fat tissue distribution and function, assessing the risk of obesity-related conditions such as metabolic syndrome (MetS) and stroke, which are strongly connected to OSA. The relationship between CMI with OSA and OSA combined with MetS (OMS) remains unclear. This study aims to evaluate the screening value of CMI for OSA and OMS, compared to the lipid accumulation product (LAP). Methods: A total of 280 participants who underwent polysomnography were finally included, with the measurements of metabolic-related laboratory test results such as total cholesterol and triglyceride. Receiver operating curve (ROC) analysis and calculation of the area under the curve (AUC) were conducted to assess the screening potential of CMI, LAP, and the logistic regression models established based on them for OSA and OMS. The Youden index, sensitivity, and specificity were used to determine the optimal cutoff points. Results: ROC curve analysis revealed that the AUCs for CMI in screening OSA and OMS were 0.808 and 0.797, and the optimal cutoff values were 0.71 (sensitivity 0.797, specificity 0.776) and 0.89 (sensitivity 0.830, specificity 0.662), respectively, showing higher Youden index than LAP. The AUCs of screening models based on CMI for OSA and OMS were 0.887 and 0.824, respectively. Conclusion: CMI and LAP can effectively screen for OSA and OMS, while CMI has more practical cutoff values for identifying the diseased states. Screening models based on CMI demonstrate a high discriminatory ability for OSA and OMS, which needs verification in a large-scale population. Keywords: obstructive sleep apnea, metabolic syndrome, cardiometabolic index, lipid accumulation products, screening model Obstructive sleep apnea (OSA) is a chronic sleep-related breathing disorder characterized by recurrent occurrences of complete or partial upper airway obstruction during sleep. 1 These pathologically result in nocturnal intermittent hypoxemia, disruptions in sleep patterns, hypercapnia, and heightened sympathetic nervous system activity. 1 Numerous studies have established that OSA is an independent factor contributing to the development and worsening of various conditions, including hypertension, gastroesophageal reflux disease (GERD), and metabolic syndrome (MetS). 2–4 MetS is a cluster of metabolic disturbances including central obesity, hyperglycemia, hypertension, and atherogenic dyslipidemia. 5 According to data from the Centers for Disease Control and Prevention in the United States, approximately 85% of individuals with type 2 diabetes also have MetS, yet the number of individuals with MetS is three times higher than that of those with type 2 diabetes. 6 MetS is a significant risk factor for the development of cardiovascular diseases, with relative risks of 1.74 for cardiovascular disease, 1.52 for coronary heart disease, and 1.76 for stroke when compared to those without MetS. 7 Due to its high prevalence and severe adverse consequences, MS has emerged as a substantial public health concern. The risk of comorbid MetS in patients with OSA is significantly higher compared to the general population. There is a mutual causal relationship between OSA and MetS, potentially forming a detrimental cycle. A lar -Abstract Truncated-
neurosciences,clinical neurology